# Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

> **NCT05666128** · PHASE2 · COMPLETED · sponsor: **Hyundai Pharm** · enrollment: 112 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** HD-6277
- **DRUG:** HD-6277
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05666128
- **Lead sponsor:** Hyundai Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-17
- **Primary completion:** 2023-06-28
- **Final completion:** 2023-07-28
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05666128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05666128, "Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05666128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*